Trupanion
TRUPNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $34.26 Prior regular-session close from the quote source.
- $33.64–$34.48 Regular-session low and high so far today.
- 330.8K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $21.16–$39.61 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own TRUP if its pet-medical-insurance model keeps solving the veterinary-cost budgeting problem while underwriting and repricing fast enough to turn scale into recurring cash profits.
TRUP price history
Loading recent earnings…
Investment thesis
What must happen next
The customer problem Trupanion targets remains urgent: pet parents continue needing a way to budget for veterinary care, so the category can keep converting rising pet-medical costs into recurring premium demand.StrengtheningMateriality: High
GAAP annual revenue increased from $698.991 million in FY2021 to $1.439305 billion in FY2025. If the budgeting need stays strong, Trupanion has a long runway for premium growth; if pet owners reject insurance as unaffordable or unnecessary, the growth engine weakens before margins matter.
Watch: Pet owners respond to premium increases by self-insuring, choosing wellness plans, or using veterinary credit instead of medical insurance.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $698.991 million in FY2021 to $1.439305 billion in FY2025.
Open source ↗Trupanion’s underwriting and repricing process can catch veterinary-cost inflation and adverse selection quickly enough that premium growth becomes economically profitable rather than just larger claims volume.StrengtheningMateriality: High
GAAP annual operating income improved from a $40.659 million loss in FY2023 to a $9.514 million loss in FY2024 and $13.837 million income in FY2025. This separates good growth from bad growth: if pricing lags claims inflation, revenue can rise while owner value is destroyed.
Watch: Veterinary-cost inflation accelerates faster than Trupanion can obtain or implement rate increases.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income improved from a $40.659 million loss in FY2023 to a $9.514 million loss in FY2024 and.
Open source ↗The recurring premium base and improved unit economics can self-fund member acquisition and operations, reducing dependence on external capital as the company scales.StrengtheningMateriality: Medium
GAAP annual operating cash flow rose from negative $8.000 million in FY2022 to positive $18.638 million in FY2023, $48.287 million in FY2024, and $89.488 million in FY2025. If growth is internally funded, per-share value can compound; if growth requires repeated capital raises or debt, shareholders may not benefit from revenue expansion.
Watch: Customer acquisition costs rise as larger insurers, retailers, or digital platforms bid more aggressively for pet-insurance leads.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow rose from negative $8.000 million in FY2022 to positive $18.638 million in FY2023, $48.287 million.
Open source ↗Trupanion’s pet-parent proposition remains differentiated enough that larger insurers and digital entrants cannot turn pet insurance into a purely price-led commodity.HoldingMateriality: Medium
GAAP diluted EPS improved from a $1.10 loss in FY2022 and $1.08 loss in FY2023 to $0.45 income in FY2025. If differentiation holds, Trupanion can retain customers through rate cycles; if the product commoditizes, pricing power and lifetime value deteriorate.
Watch: Nationwide, MetLife, Lemonade, Chewy, or another scaled channel offers comparable pet medical coverage at lower effective premiums and wins share.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP diluted EPS improved from a $1.10 loss in FY2022 and $1.08 loss in FY2023 to $0.45 income in FY2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The customer problem Trupanion targets remains urgent: pet parents continue needing a way to budget for veterinary care, so the category can keep converting rising pet-medical costs into recurring premium demand. If the budgeting need stays strong, Trupanion has a long runway for premium growth; if pet owners reject insurance as unaffordable or unnecessary, the growth engine weakens before margins matter.
Trupanion’s underwriting and repricing process can catch veterinary-cost inflation and adverse selection quickly enough that premium growth becomes economically profitable rather than just larger claims volume. This separates good growth from bad growth: if pricing lags claims inflation, revenue can rise while owner value is destroyed.
The recurring premium base and improved unit economics can self-fund member acquisition and operations, reducing dependence on external capital as the company scales. If growth is internally funded, per-share value can compound; if growth requires repeated capital raises or debt, shareholders may not benefit from revenue expansion.
Trupanion’s pet-parent proposition remains differentiated enough that larger insurers and digital entrants cannot turn pet insurance into a purely price-led commodity. If differentiation holds, Trupanion can retain customers through rate cycles; if the product commoditizes, pricing power and lifetime value deteriorate.
All standing thesis claims
Original report summary
its pet-medical-insurance model keeps solving the veterinary-cost budgeting problem while underwriting and repricing fast enough to turn scale into recurring cash profits.
Bull case and bear case
Bull case and bear case for Trupanion
Where the evidence on Trupanion stands: Holding on the latest evidence (Nov 7, 2026). Of its 4 thesis points, 3 strengthening and 1 holding.
Bull case: what the evidence supports
The customer problem Trupanion targets remains urgent: pet parents continue needing a way to budget for veterinary care, so the category can keep converting rising pet-medical costs into recurring premium demand.
Trupanion’s underwriting and repricing process can catch veterinary-cost inflation and adverse selection quickly enough that premium growth becomes economically profitable rather than just larger claims volume.
The recurring premium base and improved unit economics can self-fund member acquisition and operations, reducing dependence on external capital as the company scales.
Trupanion’s pet-parent proposition remains differentiated enough that larger insurers and digital entrants cannot turn pet insurance into a purely price-led commodity.
Bear case: what would count against it
Pet owners respond to premium increases by self-insuring, choosing wellness plans, or using veterinary credit instead of medical insurance.
Veterinary-cost inflation accelerates faster than Trupanion can obtain or implement rate increases.
Customer acquisition costs rise as larger insurers, retailers, or digital platforms bid more aggressively for pet-insurance leads.
Thesis-Break Engine
Thesis-break watch · Trupanion
No break has crossed Trupanion’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Trupanion filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Trupanion filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Trupanion filed an SEC 8-K on 2026-04-30: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Pet owners respond to premium increases by self-insuring, choosing wellness plans, or using veterinary credit instead of medical insurance.
- Veterinary-cost inflation accelerates faster than Trupanion can obtain or implement rate increases.
- Customer acquisition costs rise as larger insurers, retailers, or digital platforms bid more aggressively for pet-insurance leads.
- Nationwide, MetLife, Lemonade, Chewy, or another scaled channel offers comparable pet medical coverage at lower effective premiums and wins share.
TRUP news
Loading headlines…
Financial statements
TRUP income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
TRUP: quick answers
- What is TRUP's short interest?
- As of October 30, 2026, 3.9M TRUP shares were sold short, 9.07% of its shares outstanding, up 6.8% from the count before. At the stock's average daily volume that is 11 days to cover. FINRA publishes the count twice a month. TRUP short interest history
